Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2016.1151506 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood osteoprotegerin is associated with arteriovenous access thrombosis in hemodialysis patients.
Kidney Res Clin Pract
October 2024
Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Background: A functioning arteriovenous (AV) access is essential for hemodialysis efficiency and the quality of life in hemodialysis patients. Blood osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kappa B ligand (RANKL) have been linked to cardiovascular diseases and vascular calcification. This study investigated the relationship between blood OPG, RANKL, and the occurrence of AV access thrombosis.
View Article and Find Full Text PDFAn evodiamine derivative inhibits osteoclast differentiation and protects against OVX-induced bone loss in mice.
Clin Exp Pharmacol Physiol
December 2024
School of Medicine, Shanghai University, Shanghai, China.
Evodiamine is a biologically active alkaloid extracted from the fruit of the traditional Chinese medicine Evodia rutaecarpa (Juss.) Benth. (Fructus Evodiae, Wuzhuyu).
View Article and Find Full Text PDFA RANKL-UCHL1-sCD13 negative feedback loop limits osteoclastogenesis in subchondral bone to prevent osteoarthritis progression.
Nat Commun
October 2024
Department of Orthopaedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Article Synopsis
- Abnormal subchondral bone remodeling is crucial in osteoarthritis progression, with increased UCHL1 levels found in osteoclasts from OA patients.* -
- Deleting UCHL1 in osteoclast precursors worsens OA, while its overexpression helps reduce symptoms in male mice.* -
- The study reveals a new feedback loop involving RANKL, UCHL1, and soluble CD13 that controls osteoclast formation, suggesting a potential treatment target for OA.*
Vertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females.
Front Endocrinol (Lausanne)
October 2024
Department of Radiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Objective: To investigate the relationship between circulating receptor activator of nuclear factor-kappa B ligand (RANKL) levels and marrow adipose tissue in postmenopausal females.
Methods: A total of 164 postmenopausal females were included in the study. Serum levels of osteoprotegerin (OPG) and RANKL were measured using ELISA kits.
The Impact of Modern Bone Markers in Multiple Myeloma: Prospective Analyses Pre and Post-First Line Treatment.
Curr Issues Mol Biol
August 2024
Hematology Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400124 Cluj-Napoca, Romania.
Multiple myeloma, the disease characterized by the malignant proliferation of plasma cells that invades the bone marrow, produces osteolytic lesions and secretes monoclonal proteins. Several biomarkers have been shown to represent important tools in the pathogenesis of myeloma and offer insights into bone degradation and formation. The objectives of this current study were to assess the associations of modern biomarkers (TNF-α: tumor necrosis factor; IFN: Interferon; FreeRANKL: Free Receptor Activator for Nuclear Factor kappa B Ligand; RANKL: Receptor Activator for Nuclear Factor kappa B Ligand, Beta crosslaps, IL-6: Interleukin 6) with osteolytic lesions status after first-line treatment and to evaluate the correlations between modern and classical biomarkers (LDH: Lactate Dehydrogenase; VSH: Erythrocyte Sedimentation Rate; Hgb: Hemoglobin, Calcium, Albumin, B2microglobulin) stratified by osteolytic lesions status.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!